Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer

Michael D. Green, James L. Speyer, James C. Wernz, Nicoletta Colombo, Uziel Beller, Franco M. Muggia, E. Mark Beckman

Research output: Contribution to journalArticlepeer-review

Abstract

Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.

Original languageEnglish
Pages (from-to)333-336
Number of pages4
JournalInvestigational New Drugs
Volume8
Issue number3
DOIs
Publication statusPublished - Aug 1990

Keywords

  • 4′ deoxydoxorubicin
  • anthracycline
  • clinical trial
  • esorubicin
  • ovarian cancer

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Fingerprint

Dive into the research topics of 'Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer'. Together they form a unique fingerprint.

Cite this